

April 17, 2026

The Honorable Jacky Rosen
U.S. Senate
713 Hart Senate Office Building
Washington, DC 20510

The Honorable Ashley Moody
U.S. Senate
387 Russell Senate Office Building
Washington, DC 20510

The Honorable Beth Van Duyne
U.S. House of Representatives
1725 Longworth House Office Building
Washington, DC 20515

The Honorable Debbie Wasserman Schultz
U.S. House of Representatives
270 Cannon House Office Building
Washington, DC 20515

Dear Senator Rosen, Senator Moody, Representative Van Duyne, and Representative Wasserman Schultz,

The undersigned organizations would like to express our strong support for the *Breast Cancer Research Stamp Reauthorization Act of 2026* (S. 4318/H.R. 8358). This bipartisan legislation represents a critical opportunity to sustain a proven, innovative funding mechanism that has advanced lifesaving breast cancer research for nearly three decades.

This legislation would reauthorize the Breast Cancer Research Stamp for ten years, through 2037. Since 1998, more than 1.1 billion of these stamps have been sold in the United States, raising nearly \$98 million for cutting-edge breast cancer research. The Breast Cancer Research Stamp is a semipostal stamp used to support breast cancer research conducted by the National Institutes of Health and the Department of Defense's Congressionally Directed Medical Research Programs. This exclusive stamp, sold via the postal service for first-class mail, is charged at a higher rate than normal stamps and allows the public to contribute directly to breast cancer research. By law, the U.S. Postal Service allocates 30% of the total amount raised to the Department of Defense and 70% to the National Institute of Health. We appreciate your leadership in recognizing the importance of reauthorizing the stamp and its contribution to funding critical cancer research.

Globally, breast cancer remains the leading cause of cancer death in women. According to the National Cancer Institute, 1 in 8 women in the U.S. will be diagnosed with breast cancer during their lifetime. In 2026, it is estimated that more than 320,000 women and 2,600 men will be diagnosed with invasive breast cancer, in addition to approximately 60,000 cases of non-invasive breast cancer. Breast cancer mortality rates have declined since 1989, with larger decreases in women younger than fifty. These decreases are believed to be the result of major advances in the detection and treatment of this disease. Thanks to breakthroughs in cancer research, more patients are surviving this deadly disease. Despite this, an estimated 43,000 people will die of this disease in 2026 alone. Every dollar raised through the Breast Cancer Research Stamp can help advance discoveries and save more lives.

Thank you for your leadership and commitment to advancing policies that support lifesaving cancer research. We look forward to working with you to advance this important legislation and to ensure the continued success and progress of this vital program.

Sincerely,

Alliance for Women's Health and Prevention
American College of Obstetricians and Gynecologists
American College of Surgeons
American Medical Women's Association
American Society for Radiation Oncology
American Society of Breast Surgeons
American Society of Plastic Surgeons
Breastcancer.org
Cancer Nation
CancerCare
Check for a Lump
DenseBreast-info, Inc.
FORCE: Facing Our Risk of Cancer Empowered
HealthyWomen
Livestrong
Living Beyond Breast Cancer
Lobular Breast Cancer Alliance Inc.
Male Breast Cancer Global Alliance
Men Supporting Women With Cancer
METAvivor Research and Support
NAACP
National Association of Nurse Practitioners in Women's Health
National Black Nurses Association
National Cancer Registrars Association
National Consortium of Breast Centers
Nueva Vida
Oncology Nursing Society
Prevent Cancer Foundation
SHARE Cancer Support
Society of Breast Imaging
Susan G. Komen
The Brem Foundation to Defeat Breast Cancer
Tigerlily Foundation
Triage Cancer
Unite for HER
Young Survival Coalition